Anavex Life Sciences Corp (AVXL)

[georgejjl]

The safety of Donanemab was established with key adverse events related to Amyloid-Related Imaging Abnormalities (ARIA), ranging between 26.1 and 30.5% across the trials. There is preliminary support for delayed cognitive and functional decline with Donanemab among patients with mild-to-moderate AD.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818878/#:~:text=The%20safety%20of%20Donanemab%20was,mild%2Dto%2Dmoderate%20AD.

Good luck and GOD bless,